Skip to main content

2 Result(s)

within Article Remove this filter Jacqulyne P. Robichaux Remove this filter

and

  1. Article

    Open Access

    Structure-based classification predicts drug response in EGFR-mutant NSCLC

    Epidermal growth factor receptor (EGFR) mutations typically occur in exons 18–21 and are established driver mutations in non-small cell lung cancer (NSCLC)1–3. Targeted therapies are approved for patients with ‘c...

    Jacqulyne P. Robichaux, **uning Le, R. S. K. Vijayan, J. Kevin Hicks, Simon Heeke… in Nature (2021)

    Download PDF (9256 KB) View Article

  2. No Access

    Article

    Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

    Although most activating mutations of epidermal growth factor receptor (EGFR)-mutant non–small cell lung cancers (NSCLCs) are sensitive to available EGFR tyrosine kinase inhibitors (TKIs), a subset with altera...

    Jacqulyne P. Robichaux, Yasir Y. Elamin, Zhi Tan, Brett W. Carter… in Nature Medicine (2018)